A multicancer blood test missed its main screening goal

The headline-friendly result was fewer stage IV diagnoses. The trial's prespecified main question was different: did adding the test reduce stage III and IV cancers combined? After three annual screening rounds, it did not.

The English NHS-Galleri trial randomly assigned 142,250 people aged 50–77: 71,122 had their blood tested and 71,128 had blood stored while receiving usual care. The test was added to routine care; the trial did not compare it with replacing established screening.

Across 12 prespecified cancer types, 706 people in the test group and 688 in the control group received a stage III or IV diagnosis. The incidence-rate ratio was 1.03 (95% confidence interval 0.92–1.14; P=0.63). That does not show a reduction in the primary outcome.

Stage IV alone, a key secondary outcome, occurred in 342 versus 397 people (incidence-rate ratio 0.86; 95% confidence interval 0.74–1.00). This signal deserves follow-up, but it does not reverse the negative primary result or yet establish fewer cancer deaths.

Fewer than 1% of participants had trial-related adverse events, with none classified as serious. Mortality, downstream investigations, psychological effects and possible overdiagnosis need further reporting. Results concern this test, these 12 cancers and this age group in England; they cannot be generalized to every cancer or screening decision.

Tumor Board lens, not a live run: imagine an asymptomatic 60-year-old asking whether a headline means this blood test can replace routine screening. That is a population-screening question, not a treatment case. The trial studied an addition to usual care, so it cannot answer the replacement question. This is an editorial draft for discussion, not individual guidance.